I. Temporary inclusion of Nematrexate/ritonavir tablets in the scope of medical insurance payment
Timely adjustment of the new coronary pneumonia treatment medication into the scope of medical insurance payment, during the outbreak of the epidemic, will be "new coronary virus pneumonia diagnosis and treatment program (Trial Ninth Edition)" new Nematrexate/ritonavir tablets temporarily included in the scope of medical insurance payment according to the "A" payment, limited to the payment scope of the "A", "A" payment. "Payment is limited to "patients with confirmed diagnosis of new coronavirus pneumonia".
Second, do a good job in the new crown treatment drug supply guarantee
Autonomous region pharmaceutical procurement center to open a green channel to ensure that the new coronary pneumonia treatment drugs in a timely manner on the network, not yet listed on the network of medicines, allowing medical institutions to first offline procurement of emergency use, to protect the clinical needs.
Three, the new coronavirus antigen test reagents into the scope of payment of personal accounts
During the epidemic, the insured patients in the designated medical institutions and retail pharmacies to buy the new coronavirus antigen test reagents costs, you can use the personal accounts to pay.